Abstract
We have previously shown that the endogenous lipid palmitoylethanolamide (PEA) induced relief of neuropathic pain through an action upon receptors located on the nociceptive pathway. Recently, it has been proposed that immune cells, in particular mast cells, and microglia, by releasing algogen mediators interact with neurons to alter pain sensitivity thereby contributing to the development and maintenance of chronic pain states. The aim of this work was to explore whether the anti-nociceptive properties of PEA might be accompanied by modulation of these non-neuronal cells. Mice were subjected to a chronic constriction injury model of neuropathic pain and treated with PEA. The data show that at the earlier (3 days) time-point after nerve injury there was a substantial recruitment of mast cells whose activation was not yet pronounced. In contrast, at the later time point (8 days) there was no further increase in mast cell number, but rather a marked activation of these cells. An up-regulation of activated microglia was found in the spinal cord of neuropathic pain mice. PEA delayed mast cell recruitment, protected mast cells against degranulation and abolished the nerve growth factor increase in sciatic nerve concomitantly preserving the nerve from degeneration, while reducing microglia activation in the spinal cord. These findings support the idea that non-neuronal cells may be a valuable pharmacological target to treat neuropathic pain since the current neuronal-direct drugs are still unsatisfactory. In this context PEA could represent an innovative molecule, combining a dual analgesic activity, both on neurons and on nonneuronal cells.
Keywords: Cannabinoid, mast cell, microglia, nerve growth factor, neuropathic pain, palmitoylethanolamide, tumor necrosis factor α
CNS & Neurological Disorders - Drug Targets
Title:Non-Neuronal Cell Modulation Relieves Neuropathic Pain: Efficacy of the Endogenous Lipid Palmitoylethanolamide
Volume: 12 Issue: 1
Author(s): Isabella Bettoni, Francesca Comelli, Anita Colombo, Patrizia Bonfanti and Barbara Costa
Affiliation:
Keywords: Cannabinoid, mast cell, microglia, nerve growth factor, neuropathic pain, palmitoylethanolamide, tumor necrosis factor α
Abstract: We have previously shown that the endogenous lipid palmitoylethanolamide (PEA) induced relief of neuropathic pain through an action upon receptors located on the nociceptive pathway. Recently, it has been proposed that immune cells, in particular mast cells, and microglia, by releasing algogen mediators interact with neurons to alter pain sensitivity thereby contributing to the development and maintenance of chronic pain states. The aim of this work was to explore whether the anti-nociceptive properties of PEA might be accompanied by modulation of these non-neuronal cells. Mice were subjected to a chronic constriction injury model of neuropathic pain and treated with PEA. The data show that at the earlier (3 days) time-point after nerve injury there was a substantial recruitment of mast cells whose activation was not yet pronounced. In contrast, at the later time point (8 days) there was no further increase in mast cell number, but rather a marked activation of these cells. An up-regulation of activated microglia was found in the spinal cord of neuropathic pain mice. PEA delayed mast cell recruitment, protected mast cells against degranulation and abolished the nerve growth factor increase in sciatic nerve concomitantly preserving the nerve from degeneration, while reducing microglia activation in the spinal cord. These findings support the idea that non-neuronal cells may be a valuable pharmacological target to treat neuropathic pain since the current neuronal-direct drugs are still unsatisfactory. In this context PEA could represent an innovative molecule, combining a dual analgesic activity, both on neurons and on nonneuronal cells.
Export Options
About this article
Cite this article as:
Bettoni Isabella, Comelli Francesca, Colombo Anita, Bonfanti Patrizia and Costa Barbara, Non-Neuronal Cell Modulation Relieves Neuropathic Pain: Efficacy of the Endogenous Lipid Palmitoylethanolamide, CNS & Neurological Disorders - Drug Targets 2013; 12 (1) . https://dx.doi.org/10.2174/1871527311312010008
DOI https://dx.doi.org/10.2174/1871527311312010008 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Affective Risk for Problem Drinking: Reciprocal Influences Among Negative Urgency, Affective Lability, and Rumination
Current Drug Research Reviews The Role of Catechol-O-Methyltransferase in Reward Processing and Addiction
CNS & Neurological Disorders - Drug Targets Update of HCV in HIV-Coinfected Patients: Immunobiology and Current Treatment Options
Current Immunology Reviews (Discontinued) Leptin Plasma Levels in the General Population: Influence of Age, Gender, Body Weight and Medical History
Protein & Peptide Letters Tinnitus and Anxiety: More than Meets the Ear
Current Psychiatry Reviews Adolescent Suicide and Suicide Prevention Programs: A Comparison Between Lithuania and Flanders
Adolescent Psychiatry High Throughput Screening and Structure-Activity Relationship Study of Potential α2A-Adrenoceptor Agonists by LANCETM cAMP Assay
Combinatorial Chemistry & High Throughput Screening Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease
Current Drug Discovery Technologies An Efficient and Environmentally Benign Access Towards Synthesis of Novel 1,2,3-Triazolyl-pyrazoline Hybrids
Letters in Organic Chemistry Stem Cell Niche in Tissue Homeostasis, Aging and Cancer
Current Medicinal Chemistry Recent In Silico Research in High-Throughput Drug Discovery and Molecular Biochemistry
Current Topics in Medicinal Chemistry Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Cannabinoids (Executive Editor: Maria L. Lopez-Rodriguez)]
Mini-Reviews in Medicinal Chemistry Recent Progress in Understanding of Structure, Ligand Interactions and the Mechanism of Activation of the β 2-Adrenergic Receptor
Current Medicinal Chemistry Bio Molecular Considerations in Major Depression and Ischemic Cardiovascular Disease
Central Nervous System Agents in Medicinal Chemistry Hydrolytic Activity of Amyloid-beta and its Inhibition with Short Peptides
Current Medicinal Chemistry - Central Nervous System Agents Efficacy of the Newest COX-2 Selective Inhibitors in Rheumatic Disease
Current Pharmaceutical Design Association of rs610932 and rs670139 Polymorphisms in the MS4A Gene Cluster with Alzheimer’s Disease: An Updated Meta-analysis
Current Alzheimer Research Network Medicine and High Throughput Screening
Current Drug Discovery Technologies